Electroacupuncture Attenuated Anxiety and Depression-Like Behavior via Inhibition of Hippocampal Inflammatory Response and Metabolic Disorders in TNBS-Induced IBD Rats

Zhou, Feini; Jiang, Hao; Kong, Ning; Lin, Jiangnan; Zhang, Fan; Mai, Ting; Cao, Zhijian; Xu, Maosheng

doi:https://doi.org/10.1155/2022/8295580

Oxidative Medicine and Cellular Longevity

On this page

Abstract Introduction Materials and Methods Results Discussion Conclusions Data Availability Conflicts of Interest Authors’ Contributions Acknowledgments Supplementary Materials References Copyright Related Articles

Research Article | Open Access

Volume 2022 | Article ID 8295580 | https://doi.org/10.1155/2022/8295580

Electroacupuncture Attenuated Anxiety and Depression-Like Behavior via Inhibition of Hippocampal Inflammatory Response and Metabolic Disorders in TNBS-Induced IBD Rats

Feini Zhou,^1,2Hao Jiang,^1,2Ning Kong,^1,2Jiangnan Lin,^1,2Fan Zhang,^1,2Ting Mai,^1,2Zhijian Cao,^1,2and Maosheng Xu^1,2

Academic Editor: Kai Wang

Received13 Oct 2021

Accepted14 Dec 2021

Published18 Jan 2022

Abstract

This study was designed to explore the potential mechanisms of electroacupuncture (EA) in treating inflammatory bowel disease- (IBD-) related anxiety and mood disorders. A colitis model was induced in rats with 2, 4, 6-trinitrohydrosulfonic acid (TNBS), followed by ST36 and SP6 targeted therapy by EA or sham EA treatment. The elevated plus maze (EPM) and open-field test (OFT) were performed to assess the state of anxiety and depression-like behavior. Tests were carried out by 16S rDNA amplification sequence, ¹H nuclear magnetic resonance (¹H NMR) spectroscopy, immunofluorescence staining, and enzyme-linked immunosorbent assay (ELISA). The analyses detailed metabolic alterations and the Toll-like receptor 4 (TLR4) signaling pathway/NOD-like receptor protein 3 (NLRP3) inflammasome in rats’ hippocampal region. Furthermore, the activity of the hypothalamic-pituitary adrenal (HPA) axis and gut microbiome was assessed. As a result of treatment, EA significantly improved in the behavioral tests and altered the composition of the gut microbiome through a significant increase in the density of short chain fatty acids (SCFAs) producers mainly including Ruminococcaceae, Phascolarctobacterium, and Akkermansiaceae. EA upregulated the metabolites of the hippocampus mainly containing l-glutamine and gamma-aminobutyric acid (GABA), as well as ZO-1 expression. Whereas the treatment blocked the TLR4/nuclear factor- kappa B (NF-κB) signaling pathways and NLRP3 inflammasomes, along with downregulating the interleukin- (IL-) 1β level. The hyperactivity of the HPA axis was also diminished. In conclusion, EA at ST36 and SP6 attenuated anxiety and depression-like behavior in colitis model rats through their effects on the gut microbiome by modulating the hippocampal inflammatory response and metabolic disorders, as well as the HPA axis. This study provides evidence for clinical application of EA to serve as an adjunctive treatment for IBD-related anxiety and depression.

1. Introduction

Inflammatory bowel disease (IBD) is a group of disorders including Crohn’s disease (CD) and ulcerative colitis (UC) [1]. Both are chronic, immunological disorders with increasing incidence [2]. IBD is associated with depression [3, 4]. The incidences of psychiatric disorders are significantly higher for IBD patients when compared to the general population. A previous study reported that the prevalence of anxiety and depressive disorders in IBD patients reached 25.8% and 21.2%, respectively [5]. Recently, a study considered the prevalence to be as high as 33.1% [6].

It has been proved that anxiety and mood disorders would exacerbate IBD activity and decrease the quality of life of patients [4, 5]. Therefore, the psychophysiological vulnerability of IBD patients highlights the importance of treating their psychological requirements [7].

For traditional antidepressants, therapeutic effects can take weeks to effect [8], which would be outside the therapeutic window for most IBD patients in the acute phase. Electroacupuncture (EA) is a modern technique derived from traditional Chinese therapeutic acupuncture. The mechanism is based on the philosophy that currents spread to nearby areas and can affect peripheral nerve impulses (action potentials) more intensely [9]. When used in conjunction with medical therapy, the rapid onset of therapeutic effects could augment the antidepressant effect [10–12]. In addition, EA has anti-inflammatory effects, promotes the restoration of intestinal microecology to homeostasis, and helps to maintain mucosal tight junctions [13, 14]. Therefore, it was speculated that EA may be a promising procedure for IBD-related anxiety and depression.

Central nervous system (CNS) inflammation is associated with anxiety and mood disorders. The characteristic inflammatory response evokes the sustained activation of microglia and astrocytes and the release of inflammatory cytokines which contributes to the development of psychiatric disorders such as anxiety and depression [15, 16]. The hippocampus plays a critical function in learning and memory and could be a key brain region involved in depression [17] as alterations of hippocampal metabolomics have been discovered in depression model rats [18]. And the hypothalamic-pituitary adrenal (HPA) axis is associated with the development of anxiety, major depressive disorder, and other stress-related conditions [19]. The hippocampus showed high levels of corticosteroid receptors (GRs) which interact with corticosterone (CORT) to trigger signaling pathway and metabolic changes in the hippocampal region during the stress response [20, 21]. Moreover, through the dynamic bidirectional communication systems between the immune, metabolic, and nervous systems of the microbiome-gut-brain (MGB) axis, anxiety and depression disorders may affect alterations in gut microbiota diversity, community composition, and vice versa [22, 23]. Our previous study has supported that the disturbance of MGB axis was associated with depression-like behavior in rats [24]. Therefore, this study seeks to examine the potential mechanisms of EA treatment on the relief of IBD-related anxiety and depression.

We performed EA intervention at the acupuncture points of ST36 and SP6 on 2, 4, 6-trinitrohydrosulfonic acid- (TNBS-) induced colitis model rats. It was found that ST36 ameliorates inflammation and increases the expression of tight junction proteins [25, 26] and SP6 can relieve pain [27]. In combination, both of them can affect the HPA axis [28]. Subsequently, we conducted behavioral tests and assessed the gut microbiota by 16S rDNA amplification sequencing, detected the alteration of metabolites in the hippocampus by ¹H nuclear magnetic resonance (¹H NMR), examined the Toll-like receptor 4 (TLR4) signaling pathway/NOD-like receptor protein 3 (NLRP3) inflammasome in the hippocampal region by immunofluorescence staining, and analyzed the activity of HPA axis by enzyme-linked immunosorbent assay (ELISA). The overlap between depressive and anxiety symptoms was also observed [29].

2. Materials and Methods

2.1. Animals, Experimental Design, and Sample Collection

Experimental rats (male, 8-weeks, Sprague Dawley) were purchased from Shanghai B&K Co., Ltd. (Shanghai, China). All rats were housed in the Laboratory Animal Center of Zhejiang Chinese Medical University at and humidity with free access to autoclaved chow and water. After acclimation to the environment for 7 days, the animals were randomly divided into 3 groups (/group): control, TNBS, and TNBS + EA group. Rats fasted for 24 h (water ad libitum) and anesthesia with 3% pentobarbital was administered. TNBS solution (50 mg/kg; Sigma-Aldrich, Steinheim, Germany) dissolved in ethanol (50% ) was instilled at a dose of 1 mL/kg rat body weight for inducing the colitis model [30]. A 3 mm diameter rubber catheter was inserted 8 cm proximal to the anus. The dose was slowly administered, and the catheter was clamped in the anus for one minute to prevent solution leakage.

Symptoms of diarrhea, hematochezia, and weight loss were apparent on the first day following treatment. The control group received phosphate buffer saline (PBS (1.9 mM Na2HPO4, 8.1 mM NaH2PO4, 150 mM NaCl, pH 7.4)) instead of TNBS solution. ST36 (Zusanli, 4-5 mm lateral to the anterior tibial tuberosity) and SP6 (Sanyinjiao, 3 mm proximal to the medial malleolus at the posterior border of the tibia) were selected as the acupuncture point and inserted bilaterally to a depth of approximately 7 mm, 5 mm after disinfection, respectively [28]. The parameters were implemented with 5 Hz and 0.2 mA (Hwato, China) in the TNBS + EA group. For the sham EA, at the same treatment points, the TNBS group received electrodes without needle penetration into the skin and current was set to 0 while the control group only received topical disinfectant. All treatments were conducted for 30 min daily for consecutive 14 days. The body weight and average food intake were recorded and calculated daily for each rat. At the end of the experiment, behavioral tests were conducted and the feces were collected. The experimental procedures were shown in Figure 1(a). Hypothalamic pituitary tissues were gathered and placed in liquid nitrogen for rapid freezing. The blood samples were acquired and centrifuged (13000 RPM, 4°C, 10 min) to isolate the supernatant. Then, these samples were stored at −80°C refrigerator for ELISA analysis. The hippocampal tissues were isolated. Parts of the tissues were fixed in 4% paraformaldehyde for immunofluorescence staining, and the rest were stored in −80°C for ¹H NMR spectroscopy.

(a)

(b)

(c)

(d)

(e)

All animal experiments were conducted in accordance with the Institutional Animal Care guidelines approved by the Experimental Animal Ethical Committee of the Zhejiang Chinese Medical University (no. ZSLL-2018-014).

2.2. Behavioral Testing

The elevated plus maze (EPM) and open-field test (OFT) are commonly used in rodents to assess the exploratory and locomotor activity, unconditioned fear, and potential anxiety [31]. The EPM consists of open-arms and closed-arms that extend crosswise from the central platform. The OFT is composed of a black wall and base (the bottom surface is divided equally into 16 squares). Rats were allowed to adjust to the environment for 5 minutes. A video camera was suspended above and captured the movement of each rat for 5 min. The total number of entries, the proportion of open-arms entries [] and time spent in open-arms [] of EPM, the total movement distance, the percentage of distance spent in the central region, and the time spent in central areas of OPT were calculated by the SMART 3.0 system (Panlab, Barcelona, Spain).

2.3. 16S rDNA Sequencing and Bioinformatic Analysis

Microbial total genomic DNA of each fecal sample (200 mg) was extracted using a DNA extraction kit (E. Z. N. A. ®Stool DNA Kit, D4015, Omega, Inc., USA). The V3-V4 regions of the bacterial 16S rDNA gene were amplified with primers 341F (Forward primer: 5-CCTACGGGNGGCWGCAG-3) and 805R (Reverse primer: 5-GACTACHVGGGTATCTAATCC-3). The operation was performed as described elsewhere [32]. The feature sequences were obtained from the DADA2 core denoising function of QIIME 2 and used with the Amplicon Sequence Variants (ASVs) to construct the equivalent of 100% clustering operational classification units (OTUs). Alpha diversity and beta diversity were calculated by QIIME 2 after being normalized by the SILVA classifier (release 132). Feature sequence alignment was measured with Blast. Annotation and analysis were performed with SILVA and NT-16S databases. Graphs were generated with the R vegan package (version 3.5.2).

2.4. Sample Preparation for Metabolic Profiling

The thawed samples of the hippocampus (80 mg) and feces (100 mg) were dissolved with 800 μL of mixture of PBS with 10% deuterated water (99.8% D2O) containing 0.005% sodium 3-trimethylsilyl-propionate-d4 (TSP, SIGMA, USA), which was used as the chemical shift reference. Samples were homogenized by Tissue Lyser II (Retsch, Germany) at a frequency of 1/60 for 2 min and then centrifuged at 13000 RPM for 10 min (4°C). A volume of 500 μL of the clear supernatant was transferred to 5 mm NMR tubes for ¹H NMR measurements.

2.5. ¹H NMR Spectroscopy Analysis and Data Processing

¹H NMR was analyzed by a Bruker 600 MHz AVANCE III spectrometer equipped with a 5 mm-BBFO probe (ambient temperature 24°C). The manipulation was performed according to the previous study [24]. The defining peaks of the sample metabolites were analyzed in accordance with previous publications [33–36] and the network database of metabolomics, including the Biological Magnetic Resonance Bank (http://www.bmrb.wisc.edu/metabolomics) and the Human Metabolome Database (http://www.hmdb.ca/). The partial least squares discriminant analysis (PLS-DA) was performed using SIMCA 14.2 (Umetrics AB, Umea, Sweden) after metabolic data were normalized to constants and scaled.

2.6. Immunofluorescence Staining and Image Analysis

Hippocampus tissue was fixed with 4% paraformaldehyde for 24 h (room temperature). Sections were embedded and cut into slices, dewaxed, and soaked in antigen retrieval solutions (Citric Acid, PH6.0, G1202). Blocking was done using Bovine Serum Albumin (BSA, G5001) for 30 min and incubation at 4°C overnight with the specific primary antibodies. Then, samples were washed with PBS for and incubated with the corresponding secondary antibody (Table 1). The autofluorescence quenching agent was added, and the nucleus was restained with DAPI (G1012) and covered with antifade fluorescent mounting medium (G1401). Ultimately, the immunofluorescence results were observed with a fluorescence microscope (Nikon Eclipse C1, NIKON, Japan). The images were calculated with Image-Pro Plus 6.0 (Media Cybemetics, U.S.A). The average optical density is equal to integrated optical density divided by the area for each representative picture () and was used as variables for statistical analysis (three observed fields for each slice). All the chemical reagents were purchased from Servicebio Technology and Biotechnology Co., Ltd., China.

2.7. ELISA

The tissues of hypothalamic pituitary were thawed and homogenized in PBS solution, centrifuged at 13000 RPM, 4°C, for 10 min, and the supernatants were isolated. Serum was thawed and prepared. Then, ELISA was conducted according to the manufacturer’s protocol. The concentration of corticotropin-releasing hormone (CRH) in the hypothalamus, the adrenocorticotropic hormone (ACTH) in pituitary gland, and the contents of CRH, ACTH, and CORT in serum were measured by ELISA assay kit (Fankew, Shanghai Fankel Industrial Co., Ltd).

2.8. Statistical Analysis

Data analyses were conducted with GraphPad Prism 9.0. Differences between two groups were applied using an independent sample test. While among three groups, a one-way analysis of variance (ANOVA) followed by Bonferroni’s post hoc test was assessed. All values were expressed as (SD). The alpha diversity and beta diversity, the principal components analysis (PCA), and the principal coordinate analysis (PCoA) were tested using Wilcoxon’s rank-sum test. The relative abundance of bacteria was calculated (as X bacterial count/total count) by Kruskal-Wallis test. In all cases, the value of was defined as statistical significance.

3. Results

3.1. EA at ST36 and SP6 Alleviated Behavioral Symptoms

The average daily food intake, body weight, and colon length of rats in the TNBS group were significantly lower than that in the control group (average food intake: ; days 2-14 of body weight: ; colon length: ) but were reversed by EA treatment (average food intake: ; days 2-7 of body weight: ; colon length: ) (Figures 1(b)–1(e)).

To assess TNBS-induced anxiety and depression-like behaviors in rats and evaluate the corresponding therapeutic effects of EA, we carried out behavioral tests. In the EPM test (Figures 2(a)–2(c)), the total number of entries and percentage of entries into open-arms areas was significantly lower when treated with TNBS compared to the control. However, the proportion of entries into open-arms was significantly increased after EA treatment (). The proportion of time spent in open-arms shows no differences among the three groups. From the OFT test (Figures 2(d)–2(f)), the behavioral characteristics of the TNBS group were significantly lower compared to the control group (). And the percentage of distance and time spent in central areas was significantly increased by EA therapy (). The results suggested that EA could improve TNBS-induced anxiety and depression-like behaviors.

(a)

(b)

(c)

(d)

(e)

(f)

3.2. EA at ST36 and SP6 Changed the Gut Microbiome Composition

The alpha diversity index reflected the richness and evenness of species. As showed in Figures 3(a)–3(c), we observed that Chao1, Shannon, and Simpson indexes were the lowest in the TNBS group. But there was no statistical difference among the three groups. Beta diversity including the PCA and PCoA scatter plot represented the differences in microbiota between samples. Specifically, it showed the closer the distance, the smaller the difference in the intestinal microbiota; on the contrary, the farther the distance, the greater the difference. Obviously, the distance of the group was closer to the control group but away from the TNBS group (Figures 3(d) and 3(e); ).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

The alterations in microbial composition at the level of the top 13 phyla, 30 families, and 30 genera were analyzed based on the observed microbial species of 17 phyla, 147 families, and 313 genera, with the abundance in total coverage of approximately 99%, 99%, and 94%, respectively. The details were listed in Table 2. At the phyla level (Figure 3(f)), the relative abundance of Firmicutes was lower and Bacteroidetes was higher in the TNBS group compared to the control group, but both were reversed by EA treatment. The ratio of Firmicutes/Bacteroidetes (F/B) was raised by EA (Figure 3(g)), which was reported as a key index for a healthy state of the gut microbiome [37], and positively correlated with body weight [38]. Furthermore, after EA therapy, an increase in the relative abundance of Verrucomicrobia was also observed alongside a decrease in the level of Actinobacteria.

At the family level (Figure 3(h)), EA increased the reduction of the relative abundance of Lactobacillaceae and Acidaminococcaceae in TNBS in comparison to the control group with a significantly decreased abundance of Muribaculaceae. After EA treatment, the relative abundance of Akkermansiaceae exhibited a further increase (), which is beneficial to mucosal development [39]. Nevertheless, the relative abundance of Bifidobacteriaceae was decreased. The genus level was visualized with a heat map (Figure 3(i)). EA increased the reduction of the relative abundance of Lactobacillus, Ruminococcaceae_UCG-014, and Romboutsia in TNBS relative to the control group, but decreased the relative abundance of Muribaculaceae_unclassified () and Alistipes (opportunistic pathogen). In addition, the level of Phascolarctobacterium and Blautia was increased.

To summarize, these results indicated that EA may treat TNBS-induced colitis in rats by readjusting the gut microbiome.

3.3. EA at ST36 and SP6 Altered Metabolism in the Hippocampus

¹H NMR spectroscopy detected that there are 17 neural metabolites that were altered in the hippocampus, including l-lactic acid, myo-inositol, creatine, gamma-aminobutyric acid (GABA), N-acetyl-_L-aspartic acid (NAA), l-glutamine, glutamate/glutamine (Glu/Gln), taurine, l-glutamic acid, glycine, glycerophosphocholine (GPC), l-alanine, l-tryptophan, succinic acid, acetic acid, l-aspartic acid, and methanol. The PLS-DA scatter showed that was closer to the control but farther from the TNBS group (Figures 4(a)–4(c)), which indicated that the composition of metabolites in group has more similarity with the control group. Moreover, the model of the PLS-DA was stable and reliable, with parameters as follows: control vs. TNBS: , , ; TNBS vs. : , , (Figures 4(d) and 4(e)).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

Figure 4

EA at ST36 and SP6 altered metabolism in the hippocampus (/group). (a)–(c) PLS-DA scatter plot results of metabolites. (d) and (e) Validation model plot. (f) and (g) Differential metabolites between the control and TNBS group, and the TNBS and group, respectively. Data were shown as , , , by the independent sample test. (h) Venn diagrams demonstrate the number of altered metabolites between the control and TNBS group, the TNBS and group, and the control vs. TNBS (blue) and TNBS vs. group (pink). (i) The differential of meaningful metabolic pathways among the control, TNBS, and group.

Compared with the control group, except for the acetic acid, l-aspartic acid and methanol were increased, and the other 14 metabolites were decreased in the TNBS group (Figure 4(f)). Nevertheless, 10 metabolites containing myo-inositol, creatine, GABA, NAA, l-glutamine, taurine, GPC, l-alanine, succinic acid, and l-aspartic acid were significantly upgraded by EA treatment (), and the value of Glu/Gln is 0.064 (Figure 4(g)). Furthermore, based on the criteria of multivariate statistical analysis of both influence on projection and were used to identify significant changes in metabolites intragroup. In Venn diagrams (Figure 4(h)), a total of 11 () or 11 () metabolites were determined to be unique between the control and TNBS group. All were selected with the double criteria. In addition, 9 () or 10 () differential metabolites were determined between TNBS group and group, and 9 of them were selected with the double criteria. Taken together, there were 7 overlapping metabolites, including GABA, NAA, creatine, GPC, l-glutamine, myo-Inositol, and taurine between the control vs. TNBS and TNBS vs. group. Then, we identified the corresponding enrichment pathways for the differential metabolites through the MetaboAnalyst 5.0 website (https://www.metaboanalyst.ca/) with the condition of an impact , , and false discovery rate (FDR) value < 0.1. Accordingly, the alanine, aspartate, and glutamate metabolism pathway showed a significant difference among the three groups (Figure 4(i)). The results implied that the antianxiety and antidepressive effects of EA may be through a reversal of the amino acid metabolism pathway.

3.4. EA at ST36 and SP6 Blocked the Activation of TLR4/Nuclear Factor-Kappa B (NF-κB) Signaling Pathway and NLRP3 Inflammasomes

To verify whether EA treatment modulates this molecular signaling mechanism, we detected and quantified the TLR-4/NF-κB and MAPK and NLRP3 inflammasomes, which is a risk factor of depression [40, 41]. Immunofluorescence staining was shown in Figure 5. The indicators except IL-1β () were significantly higher in the TNBS group compared to the control group (). However, EA markedly downregulated () the expressions of Iba-1 (microglia activation marker) (Figures 5(a1)–5(b2)), TLR4 (Figures 5(a1) and 5(a2)), myeloid differentiation primary response 88 (MyD88) (Figure 5(f)), transforming growth factor-β-activated kinase 1 (TAK1) (Figure 5(g)), P-NF-κB p65 (Figures 5(c1) and 5(c2)), and interleukin- (IL-) 1β (Figures 5(d1) and 5(d2)) and improved the expressions of NLRP3 (; Figures 5(b1) and 5(b2)). There was no statistical difference in the levels of NF-κB p65; actually, P-NF-κB p65 is an essential downstream event upon TLR4 activation.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

Figure 5

EA at ST36 and SP6 blocked the activation of TLR4/NF-κB signaling pathway and NLRP3 inflammasomes (/group). Representative images of immunofluorescence staining of hippocampal slices for DAPI (blue, nuclei indicator), , , P-NF-κB p65 (red), and IL-1β (green). Original magnification ×400. (a1) and (a2) The immunofluorescence staining and histogram of . (b1) and (b2) The immunofluorescence staining and histogram of . (c1)–(c3) The immunofluorescence staining and histogram of P-NF-κB p65 and the histogram of NF-κB p65. (d1) and (d2) The immunofluorescence staining and histogram of IL-1β. (e) The histogram of ZO-1. (f) The histogram of MyD88. (g) The histogram of TAK1. (h) The histogram of p38 MAPK. (i) The histogram of P-p38 MAPK. Data were shown as . and by Bonferroni’s post hoc test.

Unexpectedly, neither the p38 mitogen-activated protein kinase (MAPK) nor the P-p38 MAPK generated a noticeable difference among the three groups (Figures 5(h) and 5(i)), suggesting that EA may not affect their expression in the hippocampus. These results indicated that TNBS induced the activation of the TLR4/NF-κB signaling pathway and NLRP3 inflammasomes and then increased the expression of IL-1β. Whereas the inflammatory cytokines were decreased by EA administration. Furthermore, we detected the expression of the tight junction protein of ZO-1 and found that EA prevented the decrease of ZO-1 in TNBS-induced rats (, Figure 5(e)). Thus, EA may have improved permeability of the blood brain barrier (BBB). The representative images of immunofluorescence staining of NF-κB p65, ZO-1, MyD88, TAK1, p38 MAPK, and P-p38 MAPK were shown in supplementary materials (available here).

3.5. EA at ST36 and SP6 Downregulated the HPA Axis Activity

Our study found that the concentrations of CRH in the hypothalamus and the CRH, ACTH, and CORT in the serum were significantly higher in the TNBS group compared with the control group (). CRH, ACTH, and CORT in serum were significantly decreased by EA treatment () (Figures 6(a)–6(e)). However, the concentrations of CRH in the hypothalamus and ACTH in the pituitary gland showed no significant difference between TNBS and group, which may be modulated by the negative feedback mechanism. In summary, EA dramatically attenuated the hyperactivity of the HPA axis.

(a)

(b)

(c)

(d)

(e)

4. Discussion

The colon length and the average food intake of rats in the TNBS group were significantly decreased compared with the control group, but increased by EA treatment. However, there was no significant weight gain from day 8 onwards. On the one hand, TNBS may cause intestinal flora dysbiosis and severely impaired intestinal function, which affects digestion and absorption. On the other hand, Turnbaugh et al. proposed that the rise in the relative abundance of Firmicutes was associated with increased energy storage, leading to obesity, while Bacteroidetes were correlated with weight loss [42]. Interestingly, the ratio of F/B in the TNBS group was the lowest among these groups, with an improved EA. This indicates that the benefits of EA in preventing weight loss during treatment may act through upregulation of the F/B ratio.

The primary source of short chain fatty acids (SCFAs) is the fermentation of indigestible dietary, which influences metabolism and mucosal immunity, maintains gut epithelial integrity, influences neuropsychiatric disorders, and improves psychological functioning, and SCFAs are therefore speculated to be mediators in the crosstalk of the MGB axis [43]. As expected, the relative abundances of SCFAs-producing bacteria, including Ruminococcaceae, Phascolarctobacterium, Akkermansiaceae, Romboutsia, and Blautia were increased by EA therapy. This may serve as evidence that EA improves anxiety and depression-like behaviors through the MGB axis mediated by SCFAs.

Moreover, the relative abundance of Lactobacillaceae was increased after EA treatment and was able to effectively alleviate intestinal inflammation [44]. Unexpectedly, our present study found that there was no improvement of the Bifidobacteriaceae levels and a decreased the relative abundance of Muribaculaceae (previously known as S24-7). The variation of microbial diversity and composition may be affected by integrated mechanisms such as individual host differences, the microbial microenvironment, and the dominant gut microbiota interaction with the host.

Previous studies have found disturbances in glutamate and lipid metabolism in the hippocampus of depressed rat models, which may reflect the function of these pathways involved in the development of depression [45]. Interestingly, the study concluded that EA markedly improved the disturbance of amino acid metabolism in the hippocampus. Glutamate is found in more than 80% of all neurons, and the glutamatergic systems play a vital role in the pathogenesis of depression [46]. GABA is the key inhibitory neurotransmitter in adult mammals, which is directly involved in anxiety and depression. Briefly, various antidepressant manipulations have been shown to increase the functional decline of GABAergic neurons, thereby improving anxiety and depressive symptoms [47, 48]. The negative behavior may be stimulated by interfering with the glutamate-glutamine-GABA cycle (Gln-Glu-GABA cycle) in the hippocampus, cerebellum, and striatum region [49]. Consistent with the above, the levels of GABA, l-glutamine, and Glu/Gln were significantly decreased in the TNBS group compared to the control group, but all of these metabolites were reversed by EA treatment. Therefore, EA may regulate the synthesis of glutamate and the production of GABA, which then contributes to the generation of cooperative action in brain regions via the Gln-Glu-GABA cycle.

EA also corrected the disturbance of myo-inositol, creatine, NAA, taurine, GPC, l-alanine, succinic acid, and l-aspartic acid. Creatine functions in the adenosine triphosphate cycle [50]. Taurine can regulate lipid metabolism and serve as an antioxidant [51]. Succinic acid is an intermediate product of the tricarboxylic acid cycle and supports the stability of gut microbiota [52]. As a result, we hypothesized that the antianxiety and depression-like effects of EA were primarily mediated through the amino acid metabolic pathway with the synergistic effects of multiple metabolites.

Microglia are considered as mediators of central immune signal transduction in psychological illness through the activation of TLR4-dependent signaling and the NLRP3 inflammasome pathway [40, 53, 54]. TLR4 stimulates the MyD88 dependent signaling pathway. This pathway signals the activation of TAK1 and phosphorylation of NF-κB p65. The TLR4/NF-κB signal pathway relieves the autoinhibition of NLRP3, which functions through the adaptor protein ASC to recruit pro-caspase-1 through its caspase recruitment domain. This then assembles together to form the NLRP3 inflammasome and shears pro-IL-1β (and pro-IL-18) into mature IL-1β (and IL-18) [55]. Consistently, our study found that IL-1β expression as well as anxiety and depression-like behavior of rats were increased in TNBS group compared to the control group, but reversed by EA treatment. Besides, the gut microbiome releases molecular metabolites that can increase the intestinal blood barrier and the permeability of the BBB [56]. The immunofluorescence staining found that the expression of ZO-1, a biomarker of permeability, showed consistent alterations with IL-1β. Thus, enhanced epithelial barrier function was necessary to anti-inflammatory cascades.

Although the NLRP3 has been the most studied inflammasome in the CNS, it is still controversial at present. Burm et al. reported that the NLRP3 may not be necessary, because the transformation of the inflammasome into a mature form of IL-1β in innate immune cells in the CNS is not strictly dependent on caspase-1 [57]. However, based on the above findings, we tend to speculate that EA enhanced BBB function and inhibited TLR4/NF-κB signaling pathway and NLRP3 inflammasome. Thereby the sequence improved inflammation and behavioral tests in TNBS-induced IBD rats.

Furthermore, previous studies suggested that activation of microglia, including activation of released NLRP3 inflammasome and IL-1β, may be induced by CORT [41, 54]. And the inflammatory cytokines directly stimulate HPA axis and indirectly alter the sensitivity of GRs to cortisol. Although GRs are widely present in brain regions and peripheral organs, the hippocampus has a high density of GRs and is thereby highly susceptible to CORT concentrations. Once released from the hypothalamus, CRH signals the release of ACTH from the anterior pituitary during the stress response. ACTH then signals for the release of corticosterone in rodents (cortisol in humans) [29, 31]. Many effects of CORT on the glutamate system are achieved by binding to GRs in the cell membrane and then further translocation to the nucleus and regulation of transcription of target genes. GABA controls epigenetic and gene transcription responses to psychological stress by suppressing the secretion of CORT [21, 58]. Taken together, our results suggest that EA may be more beneficial to the improvement of inflammation and metabolic disorders in the hippocampal region by alleviating the overactivity of the HPA axis.

There are some limitations within our study. First, the experiment is performed by inserting needles for each administration, which may induce pain in rats and generate unwanted stress effects [59]. Second, the analyses about proteins expression by immunofluorescence were limited to the observed field of view. We have not further validated methods as western blot or RT-PCR in this study. Third, many intermediate or low concentration metabolites may not be well represented in ¹H NMR, which may result in biases inherent in incomplete annotations. Thus, other techniques (e.g., liquid chromatography-tandem mass spectrometry and gas chromatography-mass spectrometry) may be necessary.

5. Conclusions

In summary, our study concluded that EA at ST36 and SP6 improved the anxiety and depressive symptoms in rats, which may be caused by the suppression of the inflammatory response of the hippocampal microglia and the overactivity of the HPA axis. Besides, EA also enhanced the BBB function and amino acid metabolism so the composition of the gut microbiota can be modulated via the MGB axis. The brain and gut microbiota likely underwent a complex interaction of bidirectional regulatory mechanisms, ultimately alleviating anxiety and depression-like behavior in TNBS-induced colitis rats (Figure 7). Though EA is a nontraditional antidepressant treatment, our study provides evidence for the clinical application of EA as an adjunctive treatment for IBD-related antianxiety and depression.

Data Availability

All data and results needed to support the conclusions of this paper are in the paper and/or supplementary materials, for additional information, please contact the authors.

Conflicts of Interest

The authors disclose no conflicts of interest.

Authors’ Contributions

MSX conceived the study design and supervised the scientific work. FNZ, HJ, and FZ performed the animal experiments. FNZ, JNL, NK, TM, and ZJC analyzed the data and prepared the graphs and tables. FNZ and HJ wrote the manuscript. MSX, NK, and FZ revised the manuscript. All authors read, reviewed, edited, and approved the final manuscript. FNZ and HJ contributed equally to this work. Feini Zhou and Hao Jiang contributed equally to this work.

Acknowledgments

This research was supported by the National Natural Science Foundation of China (no. 81971600) and the Key Research Project of Zhejiang TCM Science and Technology Plan, China (no. 2018ZZ010). The authors would like to thank Qiushuang Li from the Center of Clinical Evaluation and Analysis of the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China, for her assistance in statistical analysis in this study.

Supplementary Materials

We have provided supplementary material in a separate file. The representative images of immunofluorescence staining of NF-κB p65, ZO-1, MyD88, TAK1, p38 MAPK, and P-p38 MAPK. (Supplementary Materials)

References

L. A. Peters, J. Perrigoue, A. Mortha et al., “A functional genomics predictive network model identifies regulators of inflammatory bowel disease,” Nature Genetics, vol. 49, no. 10, pp. 1437–1449, 2017.
View at: Publisher Site | Google Scholar
S. C. Ng, H. Y. Shi, N. Hamidi et al., “Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies,” Lancet, vol. 390, no. 10114, pp. 2769–2778, 2017.
View at: Publisher Site | Google Scholar
A. D. Frolkis, I. A. Vallerand, A.-A. Shaheen et al., “Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression,” Gut, vol. 68, no. 9, pp. 1606–1612, 2019.
View at: Publisher Site | Google Scholar
D. J. Gracie, E. A. Guthrie, P. J. Hamlin, and A. C. Ford, “Bi-directionality of brain-gut interactions in patients with inflammatory bowel disease,” Gastroenterology, vol. 154, no. 6, pp. 1635–1646.e3, 2018.
View at: Publisher Site | Google Scholar
G. Byrne, G. Rosenfeld, Y. Leung et al., “Prevalence of anxiety and depression in patients with inflammatory bowel disease,” Canadian Journal of Gastroenterology & Hepatology, vol. 2017, pp. 1–6, 2017.
View at: Publisher Site | Google Scholar
X. Gao, Y. Tang, N. Lei et al., “Symptoms of anxiety/depression is associated with more aggressive inflammatory bowel disease,” Scientific Reports, vol. 11, no. 1, p. 1440, 2021.
View at: Publisher Site | Google Scholar
B. L. Bonaz and C. N. Bernstein, “Brain-gut interactions in inflammatory bowel disease,” Gastroenterology, vol. 144, no. 1, pp. 36–49, 2013.
View at: Publisher Site | Google Scholar
A. E. Autry, M. Adachi, E. Nosyreva et al., “NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses,” Nature, vol. 475, no. 7354, pp. 91–95, 2011.
View at: Publisher Site | Google Scholar
J. Y. Park and U. Namgung, “Electroacupuncture therapy in inflammation regulation: current perspectives,” Journal of Inflammation Research, vol. Volume 11, pp. 227–237, 2018.
View at: Publisher Site | Google Scholar
J. Yu, Q. Liu, Y.-Q. Wang et al., “Electroacupuncture combined with clomipramine enhances antidepressant effect in rodents,” Neuroscience Letters, vol. 421, no. 1, pp. 5–9, 2007.
View at: Publisher Site | Google Scholar
J. Yang, Y. Pei, Y. L. Pan et al., “Enhanced antidepressant-like effects of electroacupuncture combined with citalopram in a rat model of depression,” Evidence-based Complementary and Alternative Medicine, vol. 2013, 12 pages, 2013.
View at: Publisher Site | Google Scholar
J. Chen, W. Lin, S. Wang et al., “Acupuncture/electroacupuncture enhances anti-depressant effect of Seroxat: the Symptom Checklist-90 scores,” Neural Regeneration Research, vol. 9, no. 2, pp. 213–222, 2014.
View at: Publisher Site | Google Scholar
F. Liu, J. Fang, X. Shao, Y. Liang, Y. Wu, and Y. Jin, “Electroacupuncture exerts an anti-inflammatory effect in a rat tissue chamber model of inflammation via suppression of NF-κB activation,” Acupuncture in Medicine, vol. 32, no. 4, pp. 340–345, 2014.
View at: Publisher Site | Google Scholar
G.-H. Liu, H.-M. Liu, Y.-S. Chen, and T. Y. Lee, “Effect of electroacupuncture in mice with dextran sulfate sodium-induced colitis and the influence of gut microbiota,” Evidence-based Complementary and Alternative Medicine: Ecam, vol. 2020, article 2087903, pp. 1–13, 2020.
View at: Publisher Site | Google Scholar
L. Capuron and A. H. Miller, “Immune system to brain signaling: neuropsychopharmacological implications,” Pharmacology & Therapeutics, vol. 130, no. 2, pp. 226–238, 2011.
View at: Publisher Site | Google Scholar
C. Song and H. Wang, “Cytokines mediated inflammation and decreased neurogenesis in animal models of depression,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 35, no. 3, pp. 760–768, 2011.
View at: Publisher Site | Google Scholar
D. W. Roddy, C. Farrell, K. Doolin et al., “The hippocampus in depression: more than the sum of its parts? Advanced hippocampal substructure segmentation in depression,” Biological Psychiatry, vol. 85, no. 6, pp. 487–497, 2019.
View at: Publisher Site | Google Scholar
Y. Zhang, S. Yuan, J. Pu et al., “Integrated metabolomics and proteomics analysis of hippocampus in a rat model of depression,” Neuroscience, vol. 371, pp. 207–220, 2018.
View at: Publisher Site | Google Scholar
A. Menke, “Is the HPA axis as target for depression outdated, or is there a new hope?” Frontiers in Psychiatry, vol. 10, p. 101, 2019.
View at: Publisher Site | Google Scholar
W. Liu, T. Ge, Y. Leng et al., “The role of neural plasticity in depression: from hippocampus to prefrontal cortex,” Neural Plasticity, vol. 2017, Article ID 6871089, 11 pages, 2017.
View at: Publisher Site | Google Scholar
N. V. Gulyaeva, “Biochemical mechanisms and translational relevance of hippocampal vulnerability to distant focal brain injury: the price of stress response,” Biochemistry, vol. 84, no. 11, pp. 1306–1328, 2019.
View at: Publisher Site | Google Scholar
L. H. Morais, H. L. Schreiber, and S. K. Mazmanian, “The gut microbiota-brain axis in behaviour and brain disorders,” Nature Reviews Microbiology, vol. 19, no. 4, pp. 241–255, 2021.
View at: Publisher Site | Google Scholar
J. A. Foster and K.-A. McVey Neufeld, “Gut-brain axis: how the microbiome influences anxiety and depression,” Trends in Neurosciences, vol. 36, no. 5, pp. 305–312, 2013.
View at: Publisher Site | Google Scholar
F. Zhang, H. Chen, R. Zhang et al., “5-Fluorouracil induced dysregulation of the microbiome-gut-brain axis manifesting as depressive like behaviors in rats,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1866, no. 10, article 165884, 2020.
View at: Publisher Site | Google Scholar
S. Liu, Z. Wang, Y. Su et al., “A neuroanatomical basis for electroacupuncture to drive the vagal-adrenal axis,” Nature, vol. 598, no. 7882, pp. 641–645, 2021.
View at: Publisher Site | Google Scholar
H.-X. Shang, A.-Q. Wang, C.-H. Bao et al., “Moxibustion combined with acupuncture increases tight junction protein expression in Crohn’s disease patients,” World Journal of Gastroenterology, vol. 21, no. 16, pp. 4986–4996, 2015.
View at: Publisher Site | Google Scholar
C. L. Wong, K. Y. Lai, and H. M. Tse, “Effects of SP6 acupressure on pain and menstrual distress in young women with dysmenorrhea,” Complementary Therapies in Clinical Practice, vol. 16, no. 2, pp. 64–69, 2010.
View at: Publisher Site | Google Scholar
H. Zhu, S. Nan, C. Suo et al., “Electro-acupuncture affects the activity of the hypothalamic-pituitary-ovary axis in female rats,” Frontiers in Physiology, vol. 10, p. 466, 2019.
View at: Publisher Site | Google Scholar
J. F. Cryan, K. J. O'Riordan, C. S. M. Cowan et al., “The microbiota-gut-brain axis,” Physiological Reviews, vol. 99, no. 4, pp. 1877–2013, 2019.
View at: Publisher Site | Google Scholar
Z. Vochyánová, M. Pokorná, D. Rotrekl et al., “Prenylated flavonoid morusin protects against TNBS-induced colitis in rats,” PLoS One, vol. 12, no. 8, article e0182464, 2017.
View at: Publisher Site | Google Scholar
S. Wang, C. Wang, Z. Yu et al., “Agarwood essential oil ameliorates restrain stress-induced anxiety and depression by inhibiting HPA axis hyperactivity,” International Journal of Molecular Sciences, vol. 19, no. 11, p. 3468, 2018.
View at: Publisher Site | Google Scholar
W. Jing, S. Dong, X. Luo et al., “Berberine improves colitis by triggering AhR activation by microbial tryptophan catabolites,” Pharmacological Research, vol. 164, article 105358, 2021.
View at: Publisher Site | Google Scholar
A. Virel, I. Dudka, R. Laterveer, and S. af Bjerkén, “¹H NMR profiling of the 6-OHDA parkinsonian rat brain reveals metabolic alterations and signs of recovery after N -acetylcysteine treatment,” Molecular and Cellular Neurosciences, vol. 98, pp. 131–139, 2019.
View at: Publisher Site | Google Scholar
Y. Li, Z. Xie, T. Gao et al., “A holistic view of gallic acid-induced attenuation in colitis based on microbiome-metabolomics analysis,” Food & Function, vol. 10, no. 7, pp. 4046–4061, 2019.
View at: Publisher Site | Google Scholar
X. Liu, X. Zheng, G. du, Z. Li, and X. Qin, “Brain metabonomics study of the antidepressant-like effect of Xiaoyaosan on the CUMS-depression rats by ¹H NMR analysis,” Journal of Ethnopharmacology, vol. 235, pp. 141–154, 2019.
View at: Publisher Site | Google Scholar
H. Chen, F. Zhang, J. Zhang, X. Zhang, Y. Guo, and Q. Yao, “A holistic view of berberine inhibiting intestinal carcinogenesis in conventional mice based on microbiome-metabolomics analysis,” Frontiers in Immunology, vol. 11, article 588079, 2020.
View at: Publisher Site | Google Scholar
W. Lv, C. Liu, L. Yu et al., “Melatonin alleviates neuroinflammation and metabolic disorder in DSS-induced depression rats,” Oxidative Medicine and Cellular Longevity, vol. 2020, 17 pages, 2020.
View at: Publisher Site | Google Scholar
F. Magne, M. Gotteland, L. Gauthier et al., “The firmicutes/bacteroidetes ratio: a relevant marker of gut dysbiosis in obese patients?” Nutrients, vol. 12, no. 5, p. 1474, 2020.
View at: Publisher Site | Google Scholar
A. Everard, C. Belzer, L. Geurts et al., “Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity,” Proceedings of the National Academy of Sciences, vol. 110, no. 22, pp. 9066–9071, 2013.
View at: Publisher Site | Google Scholar
J. Yang, R. Liu, F. Lu et al., “Fast green FCF attenuates lipopolysaccharide-induced depressive-like behavior and downregulates TLR4/Myd 88/NF-κB signal pathway in the mouse hippocampus,” Frontiers in Pharmacology, vol. 10, p. 501, 2019.
View at: Publisher Site | Google Scholar
X. Feng, Y. Zhao, T. Yang et al., “Glucocorticoid-driven NLRP3 inflammasome activation in hippocampal microglia mediates chronic stress-induced depressive-like behaviors,” Frontiers in Molecular Neuroscience, vol. 12, p. 210, 2019.
View at: Publisher Site | Google Scholar
P. J. Turnbaugh, R. E. Ley, M. A. Mahowald, V. Magrini, E. R. Mardis, and J. I. Gordon, “An obesity-associated gut microbiome with increased capacity for energy harvest,” Nature, vol. 444, no. 7122, pp. 1027–1031, 2006.
View at: Publisher Site | Google Scholar
B. Dalile, L. van Oudenhove, B. Vervliet, and K. Verbeke, “The role of short-chain fatty acids in microbiota–gut–brain communication,” Nature Reviews Gastroenterology & Hepatology, vol. 16, no. 8, pp. 461–478, 2019.
View at: Publisher Site | Google Scholar
G. Wang, S. Huang, S. Cai et al., “Lactobacillus reuteri ameliorates intestinal inflammation and modulates gut microbiota and metabolic disorders in dextran sulfate sodium-induced colitis in mice,” Nutrients, vol. 12, no. 8, p. 2298, 2020.
View at: Publisher Site | Google Scholar
L. Liu, X. Zhou, Y. Zhang et al., “Hippocampal metabolic differences implicate distinctions between physical and psychological stress in four rat models of depression,” Translational Psychiatry, vol. 8, no. 1, pp. 1–11, 2018.
View at: Publisher Site | Google Scholar
D. Arnone, A. N. Mumuni, S. Jauhar, B. Condon, and J. Cavanagh, “Indirect evidence of selective glial involvement in glutamate-based mechanisms of mood regulation in depression: Meta-analysis of absolute prefrontal neuro- metabolic concentrations,” European Neuropsychopharmacology, vol. 25, no. 8, pp. 1109–1117, 2015.
View at: Publisher Site | Google Scholar
T. Schmidt-Wilcke, E. Fuchs, K. Funke et al., “GABA—from inhibition to cognition: emerging concepts,” The Neuroscientist, vol. 24, no. 5, pp. 501–515, 2018.
View at: Publisher Site | Google Scholar
A. V. Kalueff and D. J. Nutt, “Role of GABA in anxiety and depression,” Depression and Anxiety, vol. 24, no. 7, pp. 495–517, 2007.
View at: Publisher Site | Google Scholar
S. Xu, Y. Liu, J. Pu et al., “Chronic stress in a rat model of depression disturbs the glutamine–glutamate–GABA cycle in the striatum, hippocampus, and cerebellum,” Neuropsychiatric Disease and Treatment, vol. 16, pp. 557–570, 2020.
View at: Publisher Site | Google Scholar
M. T. J. Lowe, E. H. Kim, R. L. M. Faull, D. L. Christie, and H. J. Waldvogel, “Dissociated expression of mitochondrial and cytosolic creatine kinases in the human brain: a new perspective on the role of creatine in brain energy metabolism,” Journal of Cerebral Blood Flow & Metabolism, vol. 33, no. 8, pp. 1295–1306, 2013.
View at: Publisher Site | Google Scholar
S. Murakami, “Role of taurine in the pathogenesis of obesity,” Molecular Nutrition & Food Research, vol. 59, no. 7, pp. 1353–1363, 2015.
View at: Publisher Site | Google Scholar
J. Connors, N. Dawe, and J. Van Limbergen, “The role of succinate in the regulation of intestinal inflammation,” Nutrients, vol. 11, no. 1, p. 25, 2019.
View at: Publisher Site | Google Scholar
F. Corrigan, A. Arulsamy, L. E. Collins-Praino, J. L. Holmes, and R. Vink, “Toll like receptor 4 activation can be either detrimental or beneficial following mild repetitive traumatic brain injury depending on timing of activation,” Brain, Behavior, and Immunity, vol. 64, pp. 124–139, 2017.
View at: Publisher Site | Google Scholar
Y. Pan, X.-Y. Chen, Q.-Y. Zhang, and L. D. Kong, “Microglial NLRP3 inflammasome activation mediates IL-1β-related inflammation in prefrontal cortex of depressive rats,” Brain, Behavior, and Immunity, vol. 41, pp. 90–100, 2014.
View at: Publisher Site | Google Scholar
A. Naji, B. A. Muzembo, K.-I. Yagyu et al., “Endocytosis of indium-tin-oxide nanoparticles by macrophages provokes pyroptosis requiring NLRP3-ASC-Caspase1 axis that can be prevented by mesenchymal stem cells,” Scientific Reports, vol. 6, no. 1, article 26162, 2016.
View at: Publisher Site | Google Scholar
A. Parker, S. Fonseca, and S. R. Carding, “Gut microbes and metabolites as modulators of blood-brain barrier integrity and brain health,” Gut Microbes, vol. 11, no. 2, pp. 135–157, 2020.
View at: Publisher Site | Google Scholar
S. M. Burm, E. A. Zuiderwijk-Sick, A. E. J. ‘t Jong et al., “Inflammasome-induced IL-1β secretion in microglia is characterized by delayed kinetics and is only partially dependent on inflammatory caspases,” Journal of Neuroscience, vol. 35, no. 2, pp. 678–687, 2015.
View at: Publisher Site | Google Scholar
M. Popoli, Z. Yan, B. S. McEwen, and G. Sanacora, “The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission,” Nature Reviews Neuroscience, vol. 13, no. 1, pp. 22–37, 2011.
View at: Publisher Site | Google Scholar
H. Jin, J. Guo, J. Liu et al., “Autonomically mediated anti-inflammatory effects of electrical stimulation at acupoints in a rodent model of colonic inflammation,” Neurogastroenterology and Motility, vol. 31, no. 8, article e13615, 2019.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2022 Feini Zhou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

578

Downloads

490

Citations

Oxidative Medicine and Cellular Longevity

Electroacupuncture Attenuated Anxiety and Depression-Like Behavior via Inhibition of Hippocampal Inflammatory Response and Metabolic Disorders in TNBS-Induced IBD Rats

Abstract

1. Introduction

2. Materials and Methods

2.1. Animals, Experimental Design, and Sample Collection

2.2. Behavioral Testing

2.3. 16S rDNA Sequencing and Bioinformatic Analysis

2.4. Sample Preparation for Metabolic Profiling

2.5. 1H NMR Spectroscopy Analysis and Data Processing

2.6. Immunofluorescence Staining and Image Analysis

2.7. ELISA

2.8. Statistical Analysis

3. Results

3.1. EA at ST36 and SP6 Alleviated Behavioral Symptoms

3.2. EA at ST36 and SP6 Changed the Gut Microbiome Composition

3.3. EA at ST36 and SP6 Altered Metabolism in the Hippocampus

3.4. EA at ST36 and SP6 Blocked the Activation of TLR4/Nuclear Factor-Kappa B (NF-κB) Signaling Pathway and NLRP3 Inflammasomes

3.5. EA at ST36 and SP6 Downregulated the HPA Axis Activity

4. Discussion

5. Conclusions

Data Availability

Conflicts of Interest

Authors’ Contributions

Acknowledgments

Supplementary Materials

References

Copyright

2.5. ¹H NMR Spectroscopy Analysis and Data Processing